Supernus Pharmaceuticals has broadened its central nervous system (CNS) treatment offerings, notably by acquiring Sage Therapeutics and integrating ZURZUVAE for postpartum depression. Despite a 9% revenue increase in 2025, the company faced a substantial operating loss of $62.3 million and a net loss of $38.6 million, driven largely by acquisition-related and commercialization costs. Reliance on third-party manufacturers and collaborators like Biogen presents supply chain risks. Looking ahead, contingent milestone payments related to the Sage deal and pending regulatory approvals add financial uncertainty amid expected 17-21% top-line growth in 2026.